Relevant bibliographies by topics / Regenerative medicine (incl. stem cells)

Academic literature on the topic 'Regenerative medicine (incl. stem cells)'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Regenerative medicine (incl. stem cells).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Regenerative medicine (incl. stem cells)"

1

Sykova, Eva, and Serhiy Forostyak. "Stem Cells in Regenerative Medicine." LASER THERAPY 22, no. 2 (2013): 87–92. http://dx.doi.org/10.5978/islsm.13-re-01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Casado-Díaz, Antonio. "Stem Cells in Regenerative Medicine." Journal of Clinical Medicine 11, no. 18 (September 16, 2022): 5460. http://dx.doi.org/10.3390/jcm11185460.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rao, Mahendra. "Stem cells and regenerative medicine." Stem Cell Research & Therapy 3, no. 4 (2012): 27. http://dx.doi.org/10.1186/scrt118.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

HIRAI, Hisamaru. "Stem Cells and Regenerative Medicine." Human Cell 15, no. 4 (November 2002): 190–98. http://dx.doi.org/10.1111/j.1749-0774.2002.tb00115.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

BOHILTEA, Roxana Elena, Erick George NESTIANU, Vlad DIMA, Bianca Margareta MIHAI, Teodor SALMEN, Tiberiu Augustin GEORGESCU, Simona-Gabriela TUDORACHE, Cristina-Daniela ENACHE, and Radu VLADAREANU. "Stem cells role in regenerative medicine." Romanian Journal of Medical Practice 16, no. 4 (December 31, 2021): 428–33. http://dx.doi.org/10.37897/rjmp.2021.4.4.

Full text
Abstract:
Stem cells are precursor cells capable of self-renew and of generating numerous mature cell types. As the field of human embryonic stem cells harvesting has been put under questionable ethic issues, other sources are under investigation and present tremendous potential: tissue specific progenitor stem cells, mesenchymal stem cells, umbilical cord cells, bone marrow stem cells, and induced pluripotent stem cells. Stem cells interest different departments of regenerative medicine as well as conservative wildlife. Stem cells might be a viable option for the treatment of pathologies such as spinal injuries, cardiovascular disease, diabetes, liver injuries or even osteoarthritis. Scientists are looking forward to developing molecules that can activate tissue specific stem cells, promote stem cells to migrate to the side of tissue injury, and promote their differentiation to tissue specific cells, so that many health issues could have an alternative and efficient treatment and or even be cured.
APA, Harvard, Vancouver, ISO, and other styles
6

Han, Yu, Xuezhou Li, Yanbo Zhang, Yuping Han, Fei Chang, and Jianxun Ding. "Mesenchymal Stem Cells for Regenerative Medicine." Cells 8, no. 8 (August 13, 2019): 886. http://dx.doi.org/10.3390/cells8080886.

Full text
Abstract:
In recent decades, the biomedical applications of mesenchymal stem cells (MSCs) have attracted increasing attention. MSCs are easily extracted from the bone marrow, fat, and synovium, and differentiate into various cell lineages according to the requirements of specific biomedical applications. As MSCs do not express significant histocompatibility complexes and immune stimulating molecules, they are not detected by immune surveillance and do not lead to graft rejection after transplantation. These properties make them competent biomedical candidates, especially in tissue engineering. We present a brief overview of MSC extraction methods and subsequent potential for differentiation, and a comprehensive overview of their preclinical and clinical applications in regenerative medicine, and discuss future challenges.
APA, Harvard, Vancouver, ISO, and other styles
7

EMA, Hideo, and Hiromitsu NAKAUCHI. "Hematopoietic Stem Cells for Regenerative Medicine." TRENDS IN THE SCIENCES 14, no. 8 (2009): 16–23. http://dx.doi.org/10.5363/tits.14.8_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Verdi, Javad, Aaron Tan, Alireza Shoae-Hassani, and Alexander M. Seifalian. "Endometrial stem cells in regenerative medicine." Journal of Biological Engineering 8, no. 1 (2014): 20. http://dx.doi.org/10.1186/1754-1611-8-20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sumer, Huseyin, Jun Liu, and Sangho Roh. "Mesenchymal Stem Cells and Regenerative Medicine." Stem Cells International 2018 (October 29, 2018): 1–3. http://dx.doi.org/10.1155/2018/9810972.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ilic, D., and J. M. Polak. "Stem cells in regenerative medicine: introduction." British Medical Bulletin 98, no. 1 (May 11, 2011): 117–26. http://dx.doi.org/10.1093/bmb/ldr012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Regenerative medicine (incl. stem cells)"

1

Prasongchean, W. "Somatic stem cells : properties and potential for regenerative medicine." Thesis, University College London (University of London), 2011. http://discovery.ucl.ac.uk/1336076/.

Full text
Abstract:
Stem cells play fundamental roles in embryonic development, tissue homeostasis and have great potential in regenerative medicine. The main aims of this study were: i) to elucidate the properties and neural differentiation potential of somatic stem cells from different sources focusing on the analysis of stem cells with low immunogenicity and/or suitable for autologous cell therapy, amniotic fluid (AFSC) and adipose tissue-derived stem cells (ADSC), respectively; ii) to investigate a putative neural stem/progenitor cell niche in the choroid plexus (CP), organ that plays crucial roles in cerebrospinal fluid secretion and brain homeostasis. Unlike previously suggested, I found that AFSCs do not harbour significant neurogenic potential, as assessed by treatment with neurogenic small molecules, transplantation onto hippocampal organotypic cultures and within the chick nervous system. However, in a severe embryonic injury model grafted AFSCs reduced haemorrhage and significantly increased embryo survival via paracrine mechanisms. I then established and characterized ADSCs cultures derived from the fat of paediatric patients. They expressed markers of embryonic stem cells, mesenchymal and neural tissues, and displayed significant plasticity, as indicated by their ability to differentiate both into bone and cartilage upon appropriate stimulation, to home into the chick nervous system, and to be relatively rapidly reprogrammed to “induced pluripotent stem cells”. Altogether, though ADSCs seem more plastic than AFSCs, both provide valuable tools for developing novel therapeutic approaches and analyzing cell phenotype modulation. Finally, I showed the presence of neural precursors, neuroblasts and neuron-like cells within the CP in different species by analysis of neural markers and BrdU incorporation in vivo and in organotypic cultures, and demonstrated innervation of the CP at early developmental stages. Altogether these findings suggest the existence of a neural regulatory network within the CP that may play a crucial role in modulating its function in the developing and post-natal brain.
APA, Harvard, Vancouver, ISO, and other styles
2

Wong, J. W. "Centrifugal recovery of embryonic stem cells for regenerative medicine bioprocessing." Thesis, University College London (University of London), 2009. http://discovery.ucl.ac.uk/16358/.

Full text
Abstract:
In order to realise the potential of embryonic stem (ES) cells as a regenerative medicine, it is crucial that economical, robust and scalable bioprocesses be established. Because bioprocesses irrevocably define the safety and efficacy of any biologically derived product, an understanding of the the impact of the engineering environment on ES cells is sought. This thesis uses murine ES cells as a mimic for ES cell types that will be used in cell based regenerative medicine applications to examine the bioprocessing impact of centrifugal recovery cells. A micro scale-down approach was used to examine the effects of centrifugal force, centrifugation time and process temperature on both the yield and biological characteristics of cells subjected to batch centrifugation. When subjected to centrifugation, mES cell loss and cell damage does not appear to occur during the settling or cell pelleting. In general, 5-25% of cells are lost during pellet resuspension to recover the centrifuge cells. The level of cell loss is determined by a combination of centrifugal force, centrifugation time and process temperature. The extent of damage of the remaining cells (i.e. cells not lost during resuspension) is minimised at lower processing temperatures. It is hypothesised that at low processing temperatures, cell loss is minimised due to weak cell-to-cell contact and are thus less susceptible to damage caused by the shear environment generated to disperse the collected cell pellet. The concept of Windows of operations was also applied to evaluate an optimal set of centrifuge operating conditions that results in minimal cell loss and cell damage. The process visualisation tool indicates that operating the centrifuge at 5-9 mins x 300-500 g will result in maximum cell recovery at 4, 21 and 37oC process temperatures. The influence of centrifugation on the biological characteristics of mES cells revealed changes in proliferative capacity, pluripotency and differentiation status when exposed to varying levels of centrifugal force. mES cells exposed to increasing levels of centrifugal force up to 2,000 g progressively lost pluripotency. The pluripotency potential of cells exposed to 3,000 g of centrifugal force was not significantly different from un-centrifuged mES cells. Differentiating mES cells exposed to increasing levels of centrifugal force exhibited increased cell proliferation and a possibility of early induction of endoderm and mesoderm differentiation. Although limited in some areas, the results strongly suggest that restricting exposure to no more than low levels of centrifugal force is necessary to safeguard the stability of the desired mES cell characteristics. Overall, the insight gained from the work accomplished serves to create and establish an awareness of the challenges faced within the arena of whole cell bioprocessing for regenerative medicines.
APA, Harvard, Vancouver, ISO, and other styles
3

Chu, Pui Kei Carol. "The bioprocessing of stem cells for use in regenerative medicine." Thesis, University College London (University of London), 2009. http://discovery.ucl.ac.uk/17422/.

Full text
Abstract:
Stem cells hold great therapeutic potential in regenerative medicine due to their self-renewal capacity and their ability to differentiate into a wide range of cell lineages. This thesis is focused on the characterisation of both a pluripotent and a more specialised multipotent stem cell source. These studies involve the optimisation of essential parameters for cell expansion and differentiation. Initially, human mesenchymal stem cells (hMSCs) were used as a model system for cell expansion studies. This was followed by more advanced studies using mouse embryonic stem cells (mESC). The results obtained in this research revealed that hMSCs inoculated at low densities resulted in larger fold expansion than those inoculated at high densities. However, at low (<100 cells/cm^2) and high (10000 cells/cm^2) inoculation densities, the expression of STRO-1, a surface marker present on hMSC was lost very rapidly. The optimal inoculation density was found to be 5000 cells/cm^2. Prolonged in vitro culture of hMSCs caused a reduction in the cell proliferative potential and STRO-1 antigen expression. Therefore to preserve the ‘stemness' properties of hMSCs, expansion needs to be limited to low passage levels. The optimal fetal bovine serum concentration for hMSCs expansion was found to be at 15%. The differentiation of mESC was studied using the embryoid body (EB) system. The results obtained indicated that the size of the EB and activin A, a ligand that activates the nodal signaling pathway have profound effects on mESC lineage commitment and thus on bioprocessing. Quantitative reverse transcription-polymerase chain reaction analysis revealed that activin A enhanced and accelerated endoderm formation within small EBs, and delayed the loss of pluripotency of undifferentiated cells within large EBs. In addition, activin A has an inhibitory effect on neuroectodermal differentiation. Small EBs treated with activin A displayed a minimal neuroectodermal gene expression whereas large treated EBs displayed a higher level of expression. Finally, various in vitro culture systems for mESC differentiation were examined. These include static, rotary suspension and combined culture systems. This research provides an insight into some of the parameters affecting the growth kinetics and developmental characteristics of hMSCs and mESCs. The findings reported may help facilitate the development of successful stem cell bioprocess design essential for the scaling and manufacture of safe, efficacious and cost effective human therapies.
APA, Harvard, Vancouver, ISO, and other styles
4

Perruisseau-Carrier, Claire. "Neuronal commitment of Umbilical Cord Mesenchymal Stem Cells for brain regenerative medicine." Thesis, Lyon 1, 2013. http://www.theses.fr/2013LYO10192.

Full text
Abstract:
De nos jours, aucune prévention ou aucun remède efficace n'existe pour guérir les maladies du cerveau humain. Les cellules souches représentent un grand espoir pour la réparation et la régénération des tissus neuraux endommagés. L'objectif de cette thèse est d'évaluer la capacité des cellules souches du cordon ombilical humain (hUC MSCs) à se différencier en neurones, pour une thérapie cellulaire appliquée au cerveau. Nous avons isolé, multiplié et caractérisé les hUC MSCs naïves à l'échelle des gènes et des protéines. Ensuite, les e_ets sur l'expansion des hUC MSCs et leur différenciation neuronale de différents paramètres ont été évalués par qPCR et marquages immunologiques principalement: milieux et matrices de culture, oxygénation, culture en 3D, ainsi que divers facteurs et molécules tels que les microARNs. Les résultats montrent que les hUC MSCs prolifèrent mieux sans sérum et en conditions de normoxie du cerveau (1-5 % O2). Les hUC MSCs naïves semblent préparées à devenir des neurones à l'échelle des gènes et des protéines, mais pas suffisamment pour supporter leur complète différenciation. L'introduction de microARNs requiert des améliorations pour réguler efficacement les voies de signalisation des hUC MSCs. Au cours de cette étude, nous avons identifé les paramètres favorisant l'expansion des hUC MSCs dans des conditions compatibles avec la clinique. Cependant, une question reste ouverte: les hUC MSCs sont-elles capables de vraie transdifferentiation en neurones fonctionnels malgré les controverses? Des recherches supplémentaires sont nécessaires, mais cette étude constitue une première étape vers l'utilisation des hUC MSCs en médecine régénératrice du cerveau
Nowadays, no effective prevention or cure of human brain diseases is available. Stem cells hold great promise for the repair and regeneration of damaged neural tissues. This thesis aims to evaluate the potency of human umbilical cord mesenchymal stem cells (hUC MSCs) to be committed to the neuronal lineage, for brain cell-based therapy. To achieve this goal, naive hUC MSCs were isolated, expanded, and characterized at the gene and protein level, while particularly focusing on the neuronal lineage and clinical-grade culture conditions. Then, several parameters were investigated for hUC MSCs proliferation and neuronal commitment, including media, coatings, 3D culture, hypoxia, chemicals and molecules. Growth curves drawings, qPCRs, and immunostainings were used among other methods for identifying the best conditions for hUC MSCs expansion, differentiation, culture in 3D, and microRNAs delivery. The results indicate that hUC MSCs better proliferate in serum-free media and brain's normoxia condition (1-5 % O2). Naive hUC MSCs appear primed for neuronal fate at gene and protein level, but not su_ciently to support their neuronal di_erentiation. microRNAs delivery requires further improvement to efficiently promote neuronal signaling pathways in hUC MSCs. Along this study we identified the best parameters for hUC MSCs expansion in clinical-grade conditions. However, a question still remains: are hUC MSCs capable of full transdifferentiation towards functional neurons despite all controversies? Additional work is needed, but this study is a first step towards answering this question, bringing more clues to make transplantation of hUC MSCs for brain regenerative medicine closer
APA, Harvard, Vancouver, ISO, and other styles
5

Sutha, Ken. "Osteoinductive material derived from differentiating embryonic stem cells." Diss., Georgia Institute of Technology, 2012. http://hdl.handle.net/1853/51722.

Full text
Abstract:
The loss of regenerative capacity of bone, from fetal to adult to aged animals, has been attributed not only to a decline in the function of cells involved in bone formation but also to alterations in the bone microenvironment that occur through development and aging, including extracellular matrix (ECM) composition and growth/trophic factor content. In the development of novel treatments for bone repair, one potential therapeutic goal is the restoration of a more regenerative microenvironment, as found during embryonic development. One approach to creating such a microenvironment is through the use of stem cells. In addition to serving as a differentiated cell source, pluripotent stem cells, such as embryonic stem cells (ESCs), may possess the unique potential to modulate tissue environments via local production of ECM and growth factors. ESC-produced factors may be harnessed and delivered to promote functional tissue regeneration. Such an approach to generate a naturally derived, acelluar therapy has been employed successfully to deliver osteoinductive factors found within adult bone, in the form of demineralized bone matrix (DBM), but the development of treatments derived instead from developing, more regenerative tissues or cells remains attractive. Furthermore, the derivation of regenerative materials from an ESC source also presents the added benefit of eliminating donor to donor variability of adult, cadaveric tissue derived materials, such as DBM. Thus, the objective of this project was to examine the osteoinductive potential harbored within the embryonic microenvironment, in vitro and in vivo. The osteogenic differentiation of mouse ESCs as embryoid bodies (EBs) was evaluated in response to phosphate treatment, in vitro, including osteoinductive growth factor production. The osteoinductivity of EB-derived material (EBM) was then compared to that of adult tissue-derived DBM, in vivo. Phosphate treatment enhanced osteogenic differentiation of EBs. EBM derived from phosphate treated EBs retained bioactive, osteoinductive factors and induced new bone formation, demonstrating that the microenvironment within osteogenic EBs can be harnessed in an acellular material to yield in vivo osteoinductivity. This work not only provides new insights into the dynamic microenvironments of differentiating stem cells but also establishes an approach for the development of an ESC-derived, tissue specific therapy.
APA, Harvard, Vancouver, ISO, and other styles
6

Srivastava, Sapna. "The potential of human adipose derived stem cells for myocardial regenerative therapy." Thesis, McGill University, 2010. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=95088.

Full text
Abstract:
Background: Cell therapy using Human Bone Marrow Stem Cells (HBMSCs) has been shown to improve heart function after a myocardial infarction. The harvesting technique involved with bone marrow stem cells is invasive and yields a low cell number. There is now an increasing interest in Human Adipose Derived Stem Cells (HADSCs) as they are abundant and readily accessible from liposuction material. The present study was undertaken to investigate if HADSCs are superior than HBMSCs in myocardial regenerative therapy. Results: Both HADSCs and HBMSCs proliferated in a time dependent manner, however, the proliferative ability of HADSC was greater than HBMSCs. In addition, both cells differentiated to the osteoblast lineage confirming their multipotency when treated with induction medium. Furthermore, treatment of both cells with 5-AC resulted in positive immunostaining of cardiac markers, troponinI and connexin 43, however the expression of these markers was enhanced in HADSCs. This was further confirmed by western blot analysis, however 5-AC treatment did not exhibit cell contraction or multinucleation. In addition, these results were further confirmed by our in vivo study. Both cells were injected in the heart of a rat model of myocardial infarction and was monitored for ejection fraction (EF) and fractional shortening (FS) for 24 hours, 3 weeks and 6 weeks post-surgery. The cardiac function of the rats treated with stem cells was improved as demonstrated by increase in EF and FS, however, a greater improvement was seen with HADSCs compared with HBMSCs. This notion is further substantiated by our studies on left ventricular infarct size measurement, showing that HADSC are more potent in reduction of the infarct compared to HBMSCs. Conclusion: The data suggest that HADSCs may prove to be a more ideal alternative for regenerative therapy in the future.
La thérapie cellulaire à l'aide de cellules souches humaines de la moelle osseuses (CSHMOs) a été démontré d'améliorer la fonction cardiaque après un infarctus du myocarde. La technique de récolte des CSHMOs est pourtant invasive et donne un nombre de cellules viables faible. Il y a maintenant un intérêt croissant dans les cellules souches humaines dérivés du tissu adipeux (CSHTAs), car elles sont abondantes et facilement accessibles à partir des amas de graisses provenant des chirurgies de liposuccion. La présente étude a été menée pour vérifier si les CSHTAs sont supérieures aux CSHMOs dans la thérapie régénératrice du myocarde. Résultats: Les CSHTAs ainsi que les CSHMOs ont proliféré dans une manière temps dépendante, cependant, la capacité proliférative des CSHTAs était supérieure à celle des CSHMOs. De plus, les deux types de cellules souches ce sont différenciées en lignée ostéoblastique, affirmant leur capacité multipotent lorsqu'elles sont traitées avec le milieu d'induction. En outre, le traitement des deux types de cellules souches avec le 5-AC a entraîné l'immunomarquage positif de troponin I et de connexine 43, marqueurs cardiaques, cependant l'expression de ces marqueurs était plus robuste dans les CSHTAs. Cela a été confirmé par analyse d'immunobuvardage de type Western, cependant les cellules traité au 5-AC ne présentait pas de contraction des cellules ou le développement de plusieurs noyaux. En plus, ces résultats ont été confirmés par nos études in vivo. Les deux types de cellules ont été injectées dans le cœur d'un modèle de rat d'infarctus du myocarde et a été suivie pour la fraction d'éjection (FE) et la fraction de raccourcissement (FR) pour 24 heures, 3 semaines et 6 semaines post-chirurgie. La fonction cardiaque des rats traités avec les cellules souches a été améliorée, fait démontré par l'augmentation de l'FE et le FR, cependant, une plus grande amélioration de ce
APA, Harvard, Vancouver, ISO, and other styles
7

Yasin, Mohammed. "Non-regenerative benefits of adult bone marrow derived stem cells for myocardial protection." Thesis, Queen Mary, University of London, 2013. http://qmro.qmul.ac.uk/xmlui/handle/123456789/8701.

Full text
Abstract:
Ischaemic heart disease is the most common cause of mortality in the western hemisphere and it is rapidly becoming the leading cause of death globally. Moreover, therapeutic interventions by cardiologists and cardiac surgeons frequently subject the heart to acute I/R injury, which in itself can cause mortality. Recent investigations of adult stem cells have primarily focused on their regenerative potential for chronic ischaemic heart disease. In this thesis, I have investigated the hypothesis that adult bone marrow derived stem cells are cardioprotective in acute regional myocardial I/R injury. In a rat model of left anterior descending coronary artery (LAD) reversible occlusion and reperfusion, I demonstrate that an intravenous bolus of adult bone marrow derived (1) bone marrow mononuclear (BMNNC) and (2) mesenchymal stem cells (MSC) upon reperfusion can attenuate infarct size. This effect is comparable to ischaemic preconditioning (IPC), which is the gold standard for cardioprotection. Next, I demonstrated the mechanisms for adult stem cell cardioprotection are principally anti-apoptotic and depend upon stem cell secreted factors to (1) activate phosphatidylinositide 3-kinase (PI3)/Akt cell survival kinase-signaling pathway (2) inhibit glycogen synthase kinase-3β (3) inhibit p38MAPK (4) inhibit nuclear translocation of p65NF-κB. 7 Proteomic analysis of myocardium subjected to I/R and treated with either BMMNC or BMMNC derived supernatant (BMS) upon reperfusion demonstrated higher expression of a whole host of pro-survival proteins. These were notably (1) 14-3-3-ε protein (2) anti-oxidant peroxiredoxin-6 (3) heat shock protein (HSP) αB-crystallin, HSP72, HSP tumour necrosis factor receptor-1 associated protein, and HSP ischaemia responsive protein-94 (4) glycolytic protein glyceraldehyde-3-phosphate dehydrogenase (5) mitochondrial aconitase and mitochondrial voltage-dependent anionselective channel protein-1. Thereafter, I investigated the mobilization of endogenous bone marrow stem cells and trafficking to the ischaemic myocardium by stromal cell derived factor-1 (SDF-1) /chemokine, receptor type 4 (CXCR4) signaling. I demonstrate high up-regulated expression of CXCR4 and CD26 in BMMNC following IPC, which might have a role in IPC-mediated cardioprotection. Finally, and in concordance with this finding I demonstrate that both IPC and an exogenous MSC bolus upon reperfusion can synergize to abolish acute myocardial I/R injury.
APA, Harvard, Vancouver, ISO, and other styles
8

Williams, Kaylyn Renee. "In Vitro Models of Cellular Dedifferentiation for Regenerative Medicine." Thesis, Virginia Tech, 2018. http://hdl.handle.net/10919/83715.

Full text
Abstract:
Stem cells have the ability to self-renew and to differentiate into a variety of cell types. Stem cells can be found naturally in the body, can be derived from the inner cell mass of blastocysts, or can be made by dedifferentiation of adult cells. Regenerative medicine aims to utilize the potential of stem cells to treat disease and injury. The ability to create stem cell lines from a patient's own tissues allows for transplantation without immunosuppressive therapy as well as patient-specific disease modeling and drug testing. The objective of this study was to use cellular dedifferentiation to create in vitro cell lines with which to study regenerative medicine. First, we used siRNA targeted against myogenin to induce the dedifferentiation of murine C2C12 myotubes into myoblasts. Timelapse photography, immunofluorescence, and western blot analysis support successful dedifferentiation into myoblasts. However, the inability to separate the myotubes and myoblasts prior to siRNA treatment confounded the results. This system has the potential to be used to study mechanisms behind muscle cell regeneration and wound healing, but a better method for separating out the myoblasts needs to be developed before this will be achievable. Second, we used a doxycycline-inducible lentiviral vector encoding the transcription factors Oct4, Sox2, cMyc, and Klf4 to create a line of naive-like porcine induced pluripotent stem cells (iPSCs). This reprogramming vector was verified first in murine cells, the system in which it was developed. Successful production of both murine and porcine iPSC lines was achieved. Both showed alkaline phosphatase activity, immunofluorescence for pluripotency marker (Oct4, Sox2, and Nanog) expression, PCR for upregulation of endogenous pluripotency factors (Oct4, Sox2, cMyc, Klf4, and Nanog), and the ability to form embryoid bodies that expressed markers of all three germ layers. Additionally, we were able to create secondary porcine iPSC lines by exposing cellular outgrowths from embryoid bodies to doxycycline to initiate more efficient production of porcine iPSCs. The secondary porcine iPSCs were similar to the primary porcine iPSCs in their morphology, behavior, alkaline phosphatase expression, and Nanog expression with immunofluorescence. The porcine iPSCs were dependent on doxycycline to maintain pluripotency, indicating that they are not fully reprogrammed. Despite this dependence on doxycyline, this system can be used in the future to study the process of reprogramming, to develop directed differentiation protocols, and to model diseases.
Master of Science
APA, Harvard, Vancouver, ISO, and other styles
9

Mohrman, Ashley E. "Regenerative Medicine Approaches to Spinal Cord Injury." University of Akron / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=akron1491495476427594.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Singh, Pawanbir. "Enabling late-stage translation of regenerative medicine based products." Thesis, Loughborough University, 2010. https://dspace.lboro.ac.uk/2134/6060.

Full text
Abstract:
The primary aim of the thesis is to contribute to demonstrating how established and emerging science in the regenerative medicine (RM) domain can be translated into profitable commercial practice, and generate clinically- and cost-effective therapies. It achieves this by exploring and assessing underlying economics, including investment readiness and economic assessment, exploring regulatory and reimbursement frameworks, developing stem cell culture systems and assessing fit with clinical practice. The thesis is the first public domain wide-ranging analysis of business trends in the production, manufacturing and supply segments of the RM industry. It analyses the clinical potential of the domain as well as the translational and commercial challenges facing the industry. The industry is at a turning point as big pharmaceutical companies engage with RM in order to explore technologies as potential therapeutics and discovery tools. This unlocks the industry by confirming an exit path for RM based small- and medium-sized enterprises. Translation has come to be recognised as a core issue in the overall space and translation of regenerative therapies into the clinic is presently challenging, high-risk and expensive. This research addresses the question what are the mechanisms required to enable translation of emerging scientific knowledge into commercially viable clinical RM products? These mechanisms are particularly important as their creation involves and requires major investment decisions, which can determine the success or failure of RM developments and indeed of the companies concerned. The lack of well-established business models and the complexity of the domain suggested a conceptual approach drawing upon relevant literature from product and process development, applied business and revenue models, technological evolution and capital market ingenuity. The research was carried out in two phases. The first phase was concerned with identification of key challenges and mapping the overall industry emergence including emergence of related regulations to provide a context and framework for understanding the domain. Based on the emergence mapping a timeline of key parallel factors was identified, and their inherent connections explored to identify transforming events affecting and influencing multiple factors on the journey to clinical success within a business environment. This creates the reference model. The second phase was concerned with manufacturing a stem cell based therapeutic and applying health economic principles to determine available headroom for investment, cost of goods and return on investment, taking hearing disorders as a case exemplar, and exploring the behaviour of the net present value curve to identify key parameters affecting the economic positioning of this novel regime. A key output of the research is the investment readiness reference model. It integrates key RM business issues against reducing uncertainty and increasing value. The model argues that the complex nature of RM products means that the issues affecting industry emergence and development go well beyond the primarily scientific and technological concerns on which much current research focuses. The performance of RM firms ultimately hinges upon the successful clinical application of their developed products, the key step for creating and realising value, and their ability to deal with the fundamental business issues specific to the area. The framework deals with these business issues, which are investment & technology readiness, business models, organisational challenges, public policy and industry emergence. This thesis explores ideas that may bridge the chasm between the promise and reality of RM i.e. mechanisms to enable late stage translation of RM products. It links technological capability and business models for firms in the domain. Furthermore, it offers a unique perspective on the nature and characteristics of investment readiness and financial assessment, specifically identifying key parameters affecting economic positioning. The key contributions are therefore: New insights into the key challenges involved in realising the commercial potential of cell based therapeutics. Technology road mapping to link fundamental enabling technological capability for developing RM products with robust business plans integrating strategy, technology development and the regulatory and reimbursement framework. A generic investment readiness reference model generated from the enabling technology, value and supply chain structures to identify key indicators and characteristics of industry readiness. A novel experimental programme demonstrating expansion, maintenance and differentiation of human embryonic stem cells by manual and automated methods. New insights into economic positioning by mapping net present value, and economic analysis by estimating available headroom, cost of goods and return on investment for a putative hearing therapeutic.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Regenerative medicine (incl. stem cells)"

1

Taupin, Philippe. Stem cells and regenerative medicine. New York: Nova Science Publishers, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Stem cells in regenerative medicine. New York, N.Y: Humana, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Stem cells and regenerative medicine. New York: Nova Science Publishers, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Taupin, Philippe. Stem cells and regenerative medicine. New York: Nova Science Publishers, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Audet, Julie, and William L. Stanford, eds. Stem Cells in Regenerative Medicine. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-060-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Appasani, Krishnarao, and Raghu K. Appasani, eds. Stem Cells & Regenerative Medicine. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-60761-860-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Vertès, Alain A., Nasib Qureshi, Arnold I. Caplan, and Lee E. Babiss, eds. Stem Cells in Regenerative Medicine. Chichester, UK: John Wiley & Sons, Ltd, 2015. http://dx.doi.org/10.1002/9781118846193.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Illouz, Yves-Gérard. Adipose Stem Cells and Regenerative Medicine. Berlin, Heidelberg: Springer-Verlag Berlin Heidelberg, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fauza, Dario O., and Mahmud Bani, eds. Fetal Stem Cells in Regenerative Medicine. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3483-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Illouz, Yves-Gerard, and Aris Sterodimas, eds. Adipose Stem Cells and Regenerative Medicine. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-20012-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Regenerative medicine (incl. stem cells)"

1

Frampton, Jonathan. "Hematopoietic Stem Cells." In Regenerative Medicine, 225–46. Dordrecht: Springer Netherlands, 2010. http://dx.doi.org/10.1007/978-90-481-9075-1_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Brenner, Christoph, Robert David, and Wolfgang-Michael Franz. "Cardiovascular Stem Cells." In Regenerative Medicine, 247–63. Dordrecht: Springer Netherlands, 2010. http://dx.doi.org/10.1007/978-90-481-9075-1_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Arai, Yoko, Wieland B. Huttner, and Federico Calegari. "Neural Stem Cells." In Regenerative Medicine, 287–326. Dordrecht: Springer Netherlands, 2010. http://dx.doi.org/10.1007/978-90-481-9075-1_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Itoh, Tohru, Minoru TanakaTanaka, and Atsushi Miyajima. "Liver Stem Cells." In Regenerative Medicine, 327–49. Dordrecht: Springer Netherlands, 2010. http://dx.doi.org/10.1007/978-90-481-9075-1_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Balla, Murali MS, Anjali P. Kusumbe, Geeta K. Vemuganti, and Sharmila A. Bapat. "Cancer Stem Cells." In Regenerative Medicine, 351–76. Dordrecht: Springer Netherlands, 2010. http://dx.doi.org/10.1007/978-90-481-9075-1_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

van Buul, Gerben M., and Gerjo J. V. M. van Osch. "Musculoskeletal Stem Cells." In Regenerative Medicine, 397–417. Dordrecht: Springer Netherlands, 2010. http://dx.doi.org/10.1007/978-90-481-9075-1_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Clarke, Mary L., and Jonathan Frampton. "Hematopoietic Stem Cells." In Regenerative Medicine, 251–77. Dordrecht: Springer Netherlands, 2013. http://dx.doi.org/10.1007/978-94-007-5690-8_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Brenner, Christoph, Robert David, and Wolfgang-Michael Franz. "Cardiovascular Stem Cells." In Regenerative Medicine, 279–95. Dordrecht: Springer Netherlands, 2013. http://dx.doi.org/10.1007/978-94-007-5690-8_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Arai, Yoko, Wieland B. Huttner, and Federico Calegari. "Neural Stem Cells." In Regenerative Medicine, 297–335. Dordrecht: Springer Netherlands, 2013. http://dx.doi.org/10.1007/978-94-007-5690-8_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Itoh, Tohru, Hinako Takase, Minoru Tanaka, and Atsushi Miyajima. "Liver Stem Cells." In Regenerative Medicine, 337–63. Dordrecht: Springer Netherlands, 2013. http://dx.doi.org/10.1007/978-94-007-5690-8_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Regenerative medicine (incl. stem cells)"

1

Ahsan, Taby, Adele M. Doyle, Garry P. Duffy, Frank Barry, and Robert M. Nerem. "Stem Cells and Vascular Regenerative Medicine." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-193591.

Full text
Abstract:
Vascular applications in regenerative medicine include blood vessel substitutes and vasculogenesis in ischemic or engineered tissues. For these repair processes to be successful, there is a need for a stable supply of endothelial and smooth muscle cells. For blood vessel substitutes, the immediate goal is to enable blood flow, but vasoactivity is necessary for long term success. In engineered vessels, it is thought that endothelial cells will serve as an anti-thrombogenic lumenal layer, while smooth muscle cells contribute to vessel contractility. In other clinical applications, what is needed is not a vessel substitute but the promotion of new vessel formation (vasculogenesis). A simplified account of vasculogenesis is that endothelial cells assemble to form vessel-like structures that can then be stabilized by smooth muscle cells. Overall, the need for new vasculature to transfer oxygen and nutrients is important to reperfuse not only ischemic tissue in vivo, but also dense, structurally complex engineered tissue. The impact of these vascular therapies, however, is limited in part by the low yield and inadequate in vitro proliferation potential of primary endothelial and smooth muscle cells. Thus, there is a need to address the cell sourcing issue for vascular cell-based therapies, potentially using stem cells.
APA, Harvard, Vancouver, ISO, and other styles
2

Buang, Fhataheya, Mohamed Zulkali Mohamed Daud, and Mukhzeer Mohamad Shahimin. "Scaling up adult stem cells for regenerative medicine." In 2014 IEEE Conference on Biomedical Engineering and Sciences (IECBES). IEEE, 2014. http://dx.doi.org/10.1109/iecbes.2014.7047630.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Al Fauzi, Asra. "Intraventricular Transplantation of Autologous Bone Marrow Mesenchymal Stem Cells for Stroke: Rationale, Technique and Early Clinical Experience." In International Meeting on Regenerative Medicine. SCITEPRESS - Science and Technology Publications, 2017. http://dx.doi.org/10.5220/0007315700590064.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Апарцин, Константин, and Konstantin Apartsin. "The results of fundamental and translational research carried out In the Department of Biomedical Research and Technology of the SBRAS INC in 2012-2016." In Topical issues of translational medicine: a collection of articles dedicated to the 5th anniversary of the day The creation of a department for biomedical research and technology of the Irkutsk Scientific Center Siberian Branch of RAS. Москва: INFRA-M Academic Publishing LLC., 2017. http://dx.doi.org/10.12737/conferencearticle_58be81eca22ad.

Full text
Abstract:
The results of basic and translational research of the Department of Biomedical Research and Technology of Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences in 2012–2016 The paper presents the results of interdisciplinary research carried out in 2012–2016. The review includes the study of molecular mechanisms of pathogenesis of reparative regeneration, experimental substantiation of methods of diagnosis and prognosis of systemic disturbances of regeneration process, carrying out clinical trials of medicinal products and the formation of observational studies in the field of personalized medicine, the preparation of practical recommendations on the testing of previously developed surgical methods of prevention or correction of postoperative recovery disorders. New data are obtained on the role of the MAP-kinase cascade in the process of regeneration of muscle tissue. It has been established, that with a significant increase of VEGF concentration at the site of the repair of ischemic myocardium, progenitor cells with the CD34+CD45+ phenotype appear, which opens up prospects for the development of biotechnology to restore the damaged myocardium with its own pool of progenitor cells. The new data on the role of growth factors in the post-infarction remodeling are found. It has been revealed, that in local increase of selenium concentration low intensity of mineralization of forming callus in the area of the damage is observed and the formation of bone regeneration slows down. Prospects for the use of nanocomposites of elemental selenium for modulation of reparative response are marked. The dynamics of the level of free circulating mitochondrial DNA (mtDNA) of blood in the early stages of experimental dyslipidemia has been studied. Atherogenic blood factors do not have a significant effect on the release of the mtDNA from dyslipidemia target cells. On the model of acute small-focal myocardial ischemia, we revealed the increase in the mtDNA levels. Prospects of broadcast of diagnostic mtDNA monitoring technology in myocardial ischemia have been marked. The mtDNA monitoring was first tested as a molecular risk pattern in acute coronary syndrome. In survived patients, the concentration of freely circulating mtDNA in blood plasma was 164 times lower. The probability of death of the patient with a high level of mtDNA (over 4000 copies/mL) was 50 % (logit analysis). Methodological level of translational research in the ISC SB RAS has increased due to effective participation in international multi-center clinical trials of drugs, mainly direct anticoagulants: fondaparinux, edoksabana, betriksabana. “Feedback broadcast” of the results of clinical trials of p38-kinase inhibitor, was carried out in the process of changing the model (initially – neuropathic pain) for coronary atherosclerosis. Technologies of pharmacogenetic testing and personalized treatment of diseases in the employees of the Irkutsk Scientific Center were applied. Step T2. Previously developed at the Irkutsk State Medical University and the Irkutsk Scientific Center of Surgery and Traumatologies approaches to surgical prevention and medicinal correction of postoperative hyposplenism were translated into practical health care. Thus, these results obtained in different areas of translational medicine will determine scientific topics of the department in future research cycle.
APA, Harvard, Vancouver, ISO, and other styles
5

Bez, Maxim, Dmitriy Sheyn, Wafa Tawackoli, Pablo Avalos, Galina Shapiro, Joseph Giaconi, Xiaoyu Da, et al. "Notice of Removal: Ultrasound-mediated transfection of endogenous stem cells for regenerative medicine." In 2017 IEEE International Ultrasonics Symposium (IUS). IEEE, 2017. http://dx.doi.org/10.1109/ultsym.2017.8092153.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Divieto, C., and M. P. Sassi. "Reproducible measurements of human mesenchymal stem cells counting and proliferation in 3D scaffolds for regenerative medicine." In 2015 IEEE International Symposium on Medical Measurements and Applications (MeMeA). IEEE, 2015. http://dx.doi.org/10.1109/memea.2015.7145259.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kumar, Arun, and Binil Starly. "Modeling Human Mesenchymal Stem Cell Expansion in Vertical Wheel Bioreactors Using Lactate Production Rate in Regenerative Medicine Biomanufacturing." In ASME 2016 11th International Manufacturing Science and Engineering Conference. American Society of Mechanical Engineers, 2016. http://dx.doi.org/10.1115/msec2016-8787.

Full text
Abstract:
Stem cells are critical components of regenerative medicine therapy. However, the therapy will require millions to billions of therapeutic stem cells. To address the need, we have recently cultured stem cells in 3D microgels and used them as a vehicle for cell expansion within a low shear stress rotating wheel type bioreactor within a 500ml volumetric setting. This study specifically highlights the cell encapsulation in microbead process, harvesting and operation of microbeads within a dynamic bioreactor environment. We have specifically encapsulated stem cells (human adipose derived) into microbeads prepared from alginate hydrogels via an electrostatic jetting process. This study highlights the effect of fabrication process parameters on end-point biological quality measures such as stem cell count and viability. We were able to maintain a >80% viability during the 21 day static culture period. We have also measured the concentration of metabolites produced during the expansion, specifically lactate production measured during specific time points within culture inside the rotating wheel bioreactor Future work will need to address predicting yields in higher volume settings, efficiency of harvest and a more detailed description of the hydrodynamics affecting stem cell growth.
APA, Harvard, Vancouver, ISO, and other styles
8

Sterritt, R., R. Caines, and A. Margariti. "4 Identify novel therapies for vascular disease and regenerative medicine based on the landmark discovery of induced pluripotent stem cells." In The Scottish Cardiovascular Forum 2018, 3rd February 2018, Trinity Biomedical Science Institute, Trinity College Dublin Ireland. BMJ Publishing Group Ltd and British Cardiovascular Society, 2018. http://dx.doi.org/10.1136/heartjnl-2018-scf.14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Thirumala, Sreedhar, Jeffrey M. Gimble, and Ram V. Devireddy. "Apoptotic Response and Differentiation Ability of Adipose Derived Stem Cells (ASCs) Frozen/Thawed in the Presence of Polyvinylpyrrolidone (PVP)." In ASME 2009 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2009. http://dx.doi.org/10.1115/sbc2009-206375.

Full text
Abstract:
Effective techniques for the cryopreservation of human Adipose Stem Cells (ASCs) could increase the usefulness of these cells in tissue engineering and regenerative medicine. The traditional method of using fetal calf serum (FCS) and a chemical cryoprotectant like dimethylsulfoxide (DMSO) during freezing storage restricts the direct use of ASCs in regenerative medicine and reconstruction surgery. The objective of this study was to investigate the apoptotic, necrotic and viability response of ASCs frozen/thawed in the presence of a high molecular weight polymer, Polyvinylpyrrolidone (PVP) and in the absence of FCS. Post-freeze/thaw studies were also conducted to evaluate the effect of PVP on the in vitro osteogenic and adipogenic differentiation of ASCs. The results were compared with those obtained using the most commonly used cryopreservation media of 10%DMSO + 10% Dulbecco’s Modified Eagle Media (DMEM) + 80%FCS.
APA, Harvard, Vancouver, ISO, and other styles
10

Sudama, Hiroki, Atsushi Ogawa, Kei Saito, Wataru Ando, Norimasa Nakamura, and Hiromichi Fujie. "Effect of Shear Stress on Extracellular Matrix Production of Synovium-Derived Cells." In ASME 2009 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2009. http://dx.doi.org/10.1115/sbc2009-206331.

Full text
Abstract:
It is well known that various fibrous tissue such as tendons and ligaments functionally adapt to dynamic and static loads. Although a variety of biomechanical studies have been done to deterimine the mechanism of remodeling in fibrous tissues, it was difficult to obtain detailed information because of complicated condstitution of the tissues. We have developed a stem cell-based self-assembled tissue (scSAT) [1] for tissue engineering. Since the scSAT is consisted of synovium-derived mesenchyaml stem cells and their native extracellular matrix, it is a good experimental model to determine the process of remodeling of fibrous tisues. However, the response of shear stress to the scSAT specimen has not been determined so far, although such data are important for understanding of soft tissue remodeling and for improvement of regenerative medicine. Therefore, the present study was performed to determine the effect of shear stress on the extracellular matrix production of synovium-derived cells including mesenchymal stem cells.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Regenerative medicine (incl. stem cells)' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography